Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2592
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study ; volume:37 ; number:6 ; day:29 ; month:7 ; year:2017 ; pages:603-612 ; date:8.2017
Journal of clinical immunology ; 37, Heft 6 (29.7.2017), 603-612, 8.2017
- Keyword
-
Nichtmedikamentöse Therapie
- Creator
-
Borte, Michael
- Contributor
-
Melamed, Isaac R.
Pulka, Grazyna
Pyringer, Barbara
Knutsen, Alan P.
Ochs, Hans D.
Kobayashi, Roger H.
Kobayashi, Ai Lan
Gupta, Sudhir
Strach, Magdalena
Smits, William
Pituch-Noworolska, Anna
Moy, James N.
SpringerLink (Online service)
- DOI
-
10.1007/s10875-017-0424-4
- URN
-
urn:nbn:de:1111-201710195391
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Borte, Michael
- Melamed, Isaac R.
- Pulka, Grazyna
- Pyringer, Barbara
- Knutsen, Alan P.
- Ochs, Hans D.
- Kobayashi, Roger H.
- Kobayashi, Ai Lan
- Gupta, Sudhir
- Strach, Magdalena
- Smits, William
- Pituch-Noworolska, Anna
- Moy, James N.
- SpringerLink (Online service)
Other Objects (12)
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children
Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia
Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy
Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders
Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy
Periorbital Necrobiotic Xanthogranuloma Successfully Treated with Intravenous Immunoglobulin
Treatment of multiple system atrophy using intravenous immunoglobulin
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children
Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia
Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy
Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders
Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy
Periorbital Necrobiotic Xanthogranuloma Successfully Treated with Intravenous Immunoglobulin
Treatment of multiple system atrophy using intravenous immunoglobulin
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children
Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia
Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy
Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders
Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy
Periorbital Necrobiotic Xanthogranuloma Successfully Treated with Intravenous Immunoglobulin